Z Squared Inc. quarterly report, Q2 FY2022

Business context and reporting period

The filing is Bull Horn Holdings Corp.’s unaudited Form 10-Q for the quarter ended June 30, 2022—not a filing by Z Squared Inc., as stated in the request metadata. Bull Horn is a blank-check company that had no operating business or operating revenue. It was pursuing a business combination with Coeptis Therapeutics, Inc.

Financial results and liquidity

MetricThree months ended June 30, 2022Six months ended June 30, 2022
Operating costs$852,808$1,272,591
Operating revenueNoneNone
Net income (loss)$(204,753)$2,980,041
Operating cash flowNot separately provided$(494,012)

Six-month net income was largely attributable to a $4.197 million noncash gain from a decline in the fair value of warrant liabilities; it should not be viewed as operating profitability. The quarter’s $599,176 warrant-liability gain did not offset operating costs. Margins are not meaningful because the company had no revenue.

At June 30, 2022, cash was $84,153; trust-account securities were $32,989,082; total assets were $33,112,032; and working capital deficit was $1,128,972. Total liabilities were $4,101,922, including $948,921 of accounts payable and accrued expenses, $200,001 in related-party advances, a $103,000 fair-value carrying amount for a convertible promissory note, $600,000 of warrant liabilities, and a $2.25 million deferred underwriting fee payable. Shareholders’ deficit was $3,978,972. No operating or capital-lease obligations were reported.

Cash used in operations was $494,012 for the six months. Trust redemptions and related financing activity were substantial: $43,025,883 was withdrawn from the trust to redeem 4,258,586 public shares. The company ended the period with 3,241,414 redeemable public shares; total ordinary shares outstanding, including nonredeemable shares, were 5,116,414 as of August 9, 2022.

Material changes versus prior comparable periods

Second-quarter operating costs increased to $852,808 from $155,688 in 2021, while the quarterly net loss narrowed to $204,753 from $1,803,758. For the first six months, operating costs rose to $1,272,591 from $297,206, while net income fell to $2,980,041 from $12,269,092. The year-over-year earnings comparison was driven principally by smaller noncash gains from warrant remeasurement in 2022: $4.197 million for the first half versus $12.563 million in 2021.

Trust assets declined from $75,758,781 at December 31, 2021 to $32,989,082 at June 30, 2022, primarily following the April redemptions. Warrant liabilities also fell from $4,797,000 to $600,000, producing the reported noncash gain.

Outlook, risks, contingencies and unusual items

  • Proposed transaction: Under the April 18, 2022 merger agreement, Coeptis security holders would receive shares based on stated aggregate consideration of $175 million, adjusted for specified debt, cash, unpaid transaction expenses and bonuses. Closing was conditional; the filing gives no assurance it would occur. Bull Horn planned to redomicile in Delaware and change its name to Coeptis Therapeutics Holdings, Inc. at closing.
  • Deadline and going concern: Shareholders extended the business-combination deadline to November 3, 2022. Management said failure to complete a transaction by the deadline, absent another extension, would require liquidation and raised substantial doubt about the company’s ability to continue as a going concern. The filing reported no adjustment to asset or liability carrying values for possible liquidation.
  • Funding and fees: The sponsor agreed to fund trust deposits of $66,667 per month, up to $400,000, to support the extension; $200,001 had been deposited by June 30. The underwriters’ deferred fee was reduced from $2.25 million to $500,000 only in connection with the Coeptis transaction. The balance sheet still reported $2.25 million at quarter-end. A July 20 agreement also provided for Northland placement-agent and advisory fees for certain potential financing arrangements.
  • Financing/redemption risk: Management said the large redemptions made additional financing highly likely for a business combination. Financing may be costly or unavailable, potentially preventing closing and leading to liquidation. Public warrants may expire worthless if no business combination is completed.
  • Other risks: The filing cites uncertainty related to inflation, higher interest rates, COVID-19, geopolitical instability, proposed SEC SPAC rules, and potential Investment Company Act or CFIUS issues. No specific quantified impact was provided.
  • Controls: Disclosure controls were assessed as ineffective due to a material weakness involving complex financial instruments and redeemable shares. The company also disclosed that accrued expenses were not recorded in the proper period at June 30. Management described remediation efforts but gave no assurance they would be effective.
  • Legal proceedings: None reported. The filing provides no earnings or revenue guidance.

Most important facts for investors to verify

  1. Confirm the issuer identity: this filing is for Bull Horn Holdings Corp., not Z Squared Inc.
  2. Check the current status and final terms of the Coeptis transaction, including required approvals, redemptions, financing, debt and transaction expenses.
  3. Verify available cash, trust-account balance, sponsor extension funding, and any additional financing or backstop commitments after June 30, 2022.
  4. Reconcile the $2.25 million deferred underwriting fee reported at quarter-end with the conditional reduction to $500,000 for the Coeptis transaction.
  5. Assess progress remediating the disclosed control weakness and the effects of the unrecorded accrued expenses.
  6. Distinguish noncash warrant-valuation gains from cash generation and recurring operating performance.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.